Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 13/20 | 0.78 |
| ▸ | ESR1 | P03372 | 14/20 | 0.76 |
| ▸ | ESR2 | Q92731 | 11/20 | 0.76 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.76 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.76 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.76 |
| ▸ | CYP3A5 | P20815 | 2/20 | 0.76 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.73 |
| ▸ | MEN1 | O00255 | 1/20 | 0.73 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.73 |
| ▸ | LMNA | P02545 | 1/20 | 0.73 |
| ▸ | TP53 | P04637 | 1/20 | 0.73 |
| ▸ | MAPT | P10636 | 1/20 | 0.73 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.73 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.73 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.73 |
| ▸ | PLD2 | O14939 | 1/20 | 0.73 |
| ▸ | ESRRB | O95718 | 1/20 | 0.73 |
| ▸ | PGR | P06401 | 1/20 | 0.73 |
| ▸ | ESRRG | P62508 | 1/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18840065 | 1.00 | CYP19A1 (0.78) | CYP19A1ESR1ESR2CYP3A4CYP1A2 | |
| SCHEMBL9661905 | 1.00 | CYP19A1 (0.78) | CYP19A1ESR1ESR2CYP3A4CYP1A2 | |
| SCHEMBL10796143 | 0.94 | CYP19A1 (0.74) | CYP19A1ESR1ESR2CYP3A4CYP1A2 | |
| SCHEMBL10796138 | 0.94 | CYP19A1 (0.74) | CYP19A1ESR1ESR2CYP3A4CYP1A2 | |
| SCHEMBL8652610 | 0.90 | CYP19A1 (0.64) | CYP19A1ESR1ESR2CYP3A4CYP1A2 | |
| SCHEMBL18284333 | 0.90 | CYP19A1 (0.64) | CYP19A1ESR1ESR2CYP3A4CYP1A2 | |
| SCHEMBL18290928 | 0.90 | CYP19A1 (0.64) | CYP19A1ESR1ESR2CYP3A4CYP1A2 | |
| SCHEMBL16233656 | 0.89 | CYP19A1 (0.82) | CYP19A1ESR1ESR2CYP3A4CYP1A2 | |
| SCHEMBL18291054 | 0.89 | ESR1 (0.82) | CYP19A1ESR1ESR2CYP3A4CYP1A2 | |
| SCHEMBL10774708 | 0.89 | CYP19A1 (0.74) | CYP19A1ESR1ESR2CYP3A4CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11672758-B2 | Endoxifen methods and compositions for inhibition of protein kinase C | JINA PHARMACEUTICALS, INC. (US) | 2023-06-13 | — | — | US | disclosed |
| US-11672758-B2 | Endoxifen methods and compositions for inhibition of protein kinase C | JINA PHARMACEUTICALS, INC. (US) | 2023-06-13 | — | — | US | disclosed |
| US-20210177752-A1 | ENDOXIFEN METHODS AND COMPOSITIONS FOR INHIBITION OF PROTEIN KINASE C | JINA PHARMACEUTICALS, INC. | 2021-06-17 | — | — | US | disclosed |
| US-10376479-B2 | Endoxifen compositions and methods | JINA PHARMACEUTICALS, INC. (US) | 2019-08-13 | — | — | US | disclosed |
| US-20190231687-A1 | ENDOXIFEN METHODS AND COMPOSITIONS IN THE TREATMENT OF PSYCHIATRIC AND NEURODEGENERATIVE DISEASES | JINA PHARMACEUTICALS, INC. | 2019-08-01 | — | — | US | disclosed |
| EP-2101731-B1 | ENDOXIFEN FOR USE IN THE TREATMENT OF CANCER | JINA PHARMACEUTICALS INC (US) | 2018-01-31 | — | — | EP | disclosed |
| US-20160346230-A1 | Endoxifen Compositions And Methods | JINA PHARMACEUTICALS, INC. | 2016-12-01 | — | — | US | disclosed |
| US-20160346230-A1 | Endoxifen Compositions And Methods | JINA PHARMACEUTICALS, INC. | 2016-12-01 | — | — | US | disclosed |
| US-9333190-B2 | Endoxifen compositions and methods | JINA PHARMACEUTICALS, INC. (US) | 2016-05-10 | — | — | US | disclosed |
| US-9333190-B2 | Endoxifen compositions and methods | JINA PHARMACEUTICALS, INC. (US) | 2016-05-10 | — | — | US | disclosed |
| US-20120164075-A1 | ENDOXIFEN METHODS AND COMPOSITIONS IN THE TREATMENT OF MAMMALIAN DISEASES | JINA PHARMACEUTICALS, INC. (US) | 2012-06-28 | — | — | US | disclosed |
| WO-2010135703-A2 | ENDOXIFEN METHODS AND COMPOSITIONS IN THE TREATMENT OF MAMMALIAN DISEASES | JINA PHARMACEUTICALS, INC. (US) | 2010-11-25 | — | — | WO | disclosed |
| US-20100112041-A1 | Endoxifen Compositions And Methods | JINA PHARMACEUTICALS, INC. (US) | 2010-05-06 | — | — | US | disclosed |
| US-20100112041-A1 | Endoxifen Compositions And Methods | JINA PHARMACEUTICALS, INC. (US) | 2010-05-06 | — | — | US | disclosed |
| US-20090291134-A1 | ENDOXIFEN METHODS AND COMPOSITIONS IN THE TREATMENT OF PSYCHIATRIC AND NEURODEGENERATIVE DISEASES | JINA PHARMACEUTICALS, INC. (US) | 2009-11-26 | — | — | US | disclosed |
| US-20090291134-A1 | ENDOXIFEN METHODS AND COMPOSITIONS IN THE TREATMENT OF PSYCHIATRIC AND NEURODEGENERATIVE DISEASES | JINA PHARMACEUTICALS, INC. (US) | 2009-11-26 | — | — | US | disclosed |
| WO-2008070463-A9 | ENDOXIFEN METHODS AND COMPOSITIONS | JINA PHARMACEUTICALS INC (US) | 2008-09-18 | — | — | WO | disclosed |
| WO-2008070463-A2 | ENDOXIFEN METHODS AND COMPOSITIONS | JINA PHARMACEUTICALS, INC. (US) | 2008-06-12 | — | — | WO | disclosed |
| EP-0287690-B1 | STABLE SOLVENT ADDUCTS OF Z-1-(P-BETA-DIMETHYLAMINO-ETHOXYPHENYL)-1-(P-HYDROXYPHENYL)-2-PHENYLBUT-1-ENE | HEUMANN PHARMA GMBH & CO (DE) | 1992-09-02 | — | — | EP | disclosed |
| US-4973755-A | ANTIESTROGENS | HEUMANN PHARMA GMBH & CO. (DE) | 1990-11-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100112041-A1 | Endoxifen Compositions And Methods | CYP46A1, PLA2G2F, VDR | CYP19A1 32/4885ESR1 17/4885ESR2 23/4885 |
| US-20160346230-A1 | Endoxifen Compositions And Methods | CYP46A1, PLA2G2F, VDR | CYP19A1 32/4885ESR1 17/4885ESR2 23/4885 |
| US-20090291134-A1 | ENDOXIFEN METHODS AND COMPOSITIONS IN THE TREATMENT OF PSYCHIATRIC AND NEURODEGENERATIVE DISEASES | NLN, BDNF, LITAF | CYP19A1 655/4885ESR1 78/4885ESR2 13/4885 |
| US-10376479-B2 | Endoxifen compositions and methods | CYP46A1, PLA2G2F, VDR | CYP19A1 32/4885ESR1 17/4885ESR2 23/4885 |
| US-20120164075-A1 | ENDOXIFEN METHODS AND COMPOSITIONS IN THE TREATMENT OF MAMMALIAN DISEASES | ENPP2, ERAL1, LITAF | CYP19A1 39/4885ESR1 18/4885ESR2 4/4885 |
| US-20190231687-A1 | ENDOXIFEN METHODS AND COMPOSITIONS IN THE TREATMENT OF PSYCHIATRIC AND NEURODEGENERATIVE DISEASES | NLN, BDNF, LITAF | CYP19A1 655/4885ESR1 78/4885ESR2 13/4885 |
| US-20210177752-A1 | ENDOXIFEN METHODS AND COMPOSITIONS FOR INHIBITION OF PROTEIN KINASE C | EEF2K, LITAF, RAPGEF3 | CYP19A1 2136/4885ESR1 127/4885ESR2 25/4885 |
| US-11672758-B2 | Endoxifen methods and compositions for inhibition of protein kinase C | EEF2K, LITAF, RAPGEF3 | CYP19A1 2136/4885ESR1 127/4885ESR2 25/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.